お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
デフォルト表紙
市場調査レポート
商品コード
997535

血漿療法の世界市場

Plasma Therapy

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 128 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.20円

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

血漿療法の世界市場
出版日: 2021年04月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 128 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の血漿療法の市場規模は、分析期間(2020年~2027年)に13.3%のCAGRで成長する見通しで、2020年の1億9,590万米ドルから、2027年には4億7,060万米ドルに達すると予測されています。

当レポートで分析されているセグメントの1つである純粋PRPは、分析期間中に12.5%のCAGRで成長し、2億3,290万米ドルに達すると予測されています。

当レポートは、世界の血漿療法市場について調査しており、市場シェア、Covid-19の影響、動向や成長要因、地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

調査対象企業の例

  • Bio Products Laboratory Ltd.
  • Biolife Plasma Services
  • Biotest AG
  • Cambryn Biologics LLC
  • China Biologic Products, Inc.
  • CSL Ltd.
  • Grifols International SA
  • Kedrion SpA
  • LFB SA
  • Octapharma AG

目次

I. 調査手法

II. エグゼクティブサマリー

  • 市場概要
    • インフルエンサー市場の洞察
    • 世界市場の軌跡
    • Covid-19の影響と迫り来る世界の景気後退
  • 主要企業
  • 動向と推進要因
  • 世界市場の見通し

III. 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

IV. 競合

  • 企業プロファイル:38社
目次
Product Code: MCP14017

Abstract:

Global Plasma Therapy Market to Reach $470.6 Million by 2027

Amid the COVID-19 crisis, the global market for Plasma Therapy estimated at US$195.9 Million in the year 2020, is projected to reach a revised size of US$470.6 Million by 2027, growing at a CAGR of 13.3% over the analysis period 2020-2027. Pure PRP, one of the segments analyzed in the report, is projected to record a 12.5% CAGR and reach US$232.9 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Leukocyte-Rich PRP segment is readjusted to a revised 15.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $57.8 Million, While China is Forecast to Grow at 12.9% CAGR

The Plasma Therapy market in the U.S. is estimated at US$57.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$82.4 Million by the year 2027 trailing a CAGR of 12.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.6% and 11.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9.8% CAGR.

Pure Platelet-Rich Fibrin Segment to Record 13.6% CAGR

In the global Pure Platelet-Rich Fibrin segment, USA, Canada, Japan, China and Europe will drive the 13.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$22.5 Million in the year 2020 will reach a projected size of US$54.5 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$56.2 Million by the year 2027.

Select Competitors (Total 38 Featured) -

  • Bio Products Laboratory Ltd.
  • Biolife Plasma Services
  • Biotest AG
  • Cambryn Biologics LLC
  • China Biologic Products, Inc.
  • CSL Ltd.
  • Grifols International SA
  • Kedrion SpA
  • LFB SA
  • Octapharma AG

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Plasma Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Plasma Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Plasma Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Pure PRP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Pure PRP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Pure PRP by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Leukocyte-Rich PRP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Leukocyte-Rich PRP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Leukocyte-Rich PRP by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Pure Platelet-Rich Fibrin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Pure Platelet-Rich Fibrin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Pure Platelet-Rich Fibrin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Leukocyte-Rich Fibrin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Leukocyte-Rich Fibrin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Leukocyte-Rich Fibrin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 16: USA Current & Future Analysis for Plasma Therapy by Type - Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 17: USA Historic Review for Plasma Therapy by Type - Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 18: USA 15-Year Perspective for Plasma Therapy by Type - Percentage Breakdown of Value Sales for Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 19: Canada Current & Future Analysis for Plasma Therapy by Type - Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 20: Canada Historic Review for Plasma Therapy by Type - Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 21: Canada 15-Year Perspective for Plasma Therapy by Type - Percentage Breakdown of Value Sales for Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 22: Japan Current & Future Analysis for Plasma Therapy by Type - Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 23: Japan Historic Review for Plasma Therapy by Type - Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 24: Japan 15-Year Perspective for Plasma Therapy by Type - Percentage Breakdown of Value Sales for Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 25: China Current & Future Analysis for Plasma Therapy by Type - Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 26: China Historic Review for Plasma Therapy by Type - Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 27: China 15-Year Perspective for Plasma Therapy by Type - Percentage Breakdown of Value Sales for Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 28: Europe Current & Future Analysis for Plasma Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
    • TABLE 29: Europe Historic Review for Plasma Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 30: Europe 15-Year Perspective for Plasma Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 31: Europe Current & Future Analysis for Plasma Therapy by Type - Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Europe Historic Review for Plasma Therapy by Type - Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 33: Europe 15-Year Perspective for Plasma Therapy by Type - Percentage Breakdown of Value Sales for Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 34: France Current & Future Analysis for Plasma Therapy by Type - Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 35: France Historic Review for Plasma Therapy by Type - Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 36: France 15-Year Perspective for Plasma Therapy by Type - Percentage Breakdown of Value Sales for Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 37: Germany Current & Future Analysis for Plasma Therapy by Type - Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Germany Historic Review for Plasma Therapy by Type - Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 39: Germany 15-Year Perspective for Plasma Therapy by Type - Percentage Breakdown of Value Sales for Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 40: Italy Current & Future Analysis for Plasma Therapy by Type - Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Italy Historic Review for Plasma Therapy by Type - Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 42: Italy 15-Year Perspective for Plasma Therapy by Type - Percentage Breakdown of Value Sales for Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 43: UK Current & Future Analysis for Plasma Therapy by Type - Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 44: UK Historic Review for Plasma Therapy by Type - Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 45: UK 15-Year Perspective for Plasma Therapy by Type - Percentage Breakdown of Value Sales for Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 46: Rest of Europe Current & Future Analysis for Plasma Therapy by Type - Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Rest of Europe Historic Review for Plasma Therapy by Type - Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 48: Rest of Europe 15-Year Perspective for Plasma Therapy by Type - Percentage Breakdown of Value Sales for Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 49: Asia-Pacific Current & Future Analysis for Plasma Therapy by Type - Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Asia-Pacific Historic Review for Plasma Therapy by Type - Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 51: Asia-Pacific 15-Year Perspective for Plasma Therapy by Type - Percentage Breakdown of Value Sales for Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 52: Rest of World Current & Future Analysis for Plasma Therapy by Type - Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Rest of World Historic Review for Plasma Therapy by Type - Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 54: Rest of World 15-Year Perspective for Plasma Therapy by Type - Percentage Breakdown of Value Sales for Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 38
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.